Company intelligence / Profile preview

Lingyi Biotechnology

Hangzhou, Zhejiang Sheng, Chinaorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

LY-M001 injection for Gaucher's disease has received IND approval from both FDA and NMPA (China) and has begun Phase I clinical trials. Preliminary data shows good safety and efficacy in both adult and pediatric patients. LY-M003 injection for Wilson's disease has launched clinical studies and has received FDA Orphan Drug Design (ODD) and Rare Pediatric Disease Design (RPDD) accreditation.

Therapeutic areas: OphthalmologyRare DiseasesNeurology
Modalities: Gene therapyAAV-based gene therapyBiological products
Industry: Biotech

Drug pipeline

2 assets

LY-M001

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Lingyi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lingyi Biotechnology.

Explore the full profile